PM-CAR1035 CD19-CD22-4-1BB-CD3 ZETA PMC-250€¦ · in Figure 1). ProMab has also generated CAR-T cells and CAR-NK (Natural Killer) effector cells against cancer target cells that

ProMab Biotechnologies, Inc. | 2600 Hilltop Drive, Building B, Suite C320, Richmond, CA 94806 USAToll free 1-866-339-0871 | 1-510-860-4615 (Sales) | 1-510-860-4614 (Technical Support) | Fax 1-510-740-3625 | [email protected] | www.ProMab.com

1

Products and Services

Mouse Monoclonal Antibody

Rat Monoclonal Antibody

Human Antibody

Hybridoma Sequencing

Polyclonal Antibody

Promab Biotechnologies’ CAR-T new product development programs are being designed for pre-clinical and future clinical applications.

CAR-T cells can be used for:

1. Compound screening

2. Antibody screening

3. Co-stimulatory and activation domain comparison

4. Personalized medicine and donor variations for CAR-T screening

5. Checkpoint inhibitors

6. Safety switches and regulators of CAR-T functions

7. Pre-clinical in vivo models

8. Treg and T memory cells in CAR-T setting

9. CAR-T signaling, tumor microenvironment

10. Proof of concept studies for clinical trials

Figure 1. CAR-T cells expressing the above constructs are available from ProMab targeting CD19 and CD22 antigens. ScFv means single chain variable fragment. These CAR-T cells are generated with CD19-CD22-4-1BB-CD3 zeta CAR construct.

To date, ProMab has generated 2nd generation CAR and CAR controls (as shown

in Figure 1). ProMab has also generated CAR-T cells and CAR-NK (Natural Killer) effector cells against cancer target cells that show excellent functionality, including dose-dependent and target cell-specific cytotoxic activity.

These CAR-T cells can be tested with target cells in cytotoxic assays and used for testing modulators of immune checkpoint inhibitors (PD-1, CTLA-4 pathways), activators of immune response, or small molecules affecting T-cell or T-reg activity.

The structure of CAR from PromabCD19 and CD22 proteins are often overexpressed in leukemia and lymphoma.Both CAR-T cells are used for targeting these hematological diseases. CAR-T cells targeting both antigens is developed to target these antigens simultaneously.




Human Antibody


Polyclonal Antibody

Ready-to use-CAR-T cells PM-CAR1035 CD19-CD22-4-1BB-CD3 ZETA PMC-250

CD19-22 CAR construct

CD22 ScFvVH-VL

GM-CSFleader

CD8 hinge

4-1BBTMCD8 CD3 zetaCD19

VL CD19

VH


2




Human Antibody


Polyclonal Antibody

Figure 3. Top panel: RTCA cytotoxicity activity of effector CD19-CD22-4-1BB-CD3-CAR-T cells against Hela-CD19 target cells. This shows killing of CD19-positive target cells by CD19-CD22-CAR-T cells. Lower panel: RTCA cytotoxicity activity of effector CDCD19-22-4-1BB-CD3-CAR-T cells against CHO-CD22 target cells available from Promab. This shows killing of CD22-positive cells by CD19-CD22-CAR-T cells. Effector cells: Target cells ratio=10:1.




Human Antibody


Polyclonal Antibody

Data

104104 104 104

103103 103 103

102102

102 102

101101

101 101

100100

100 100

100100

100100

101101

101101

102102

102102

103103

103103

104104

104104

Figure 2. FACS analysis with human FAB antibody detects CD22 CAR and FACS with CD19ScFv (FMC63, available from ProMab) shows expression of CD19-CAR.

FL4-

H::C

D3A

PC

FL4-

H::C

D3A

PC

FL4-

H::C

D3A

PC

FL4-

H::C

D3A

PC

CD22-41BB-CD3 CAR-T cells

T cells

Cells alone

CD19-CD22-41BB-CD3 CAR-T cells

Nor

mal

ized

Cel

l Ind

ex

1.6

1.4

1.2

1.0

0.8

0.6

0.4

0.2

0.00.0 10.0 20.0 30.0

Time (in Hour)

Hela-CD19 cells

CD19-CD22-41BBCD3 CAR-T cells

4

3

2

1

05.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0

Time (in Hour)

Cell

Inde

x

0.0(30.98,3.8400)

CHO-CD22 cells



3




Human Antibody


Polyclonal Antibody




Human Antibody


Polyclonal Antibody

Data

Figure 4. RTCA cytotoxicity activity of effector CD19-CD22-4-1BB-CD3-CAR-T cells against Raji target cells.

Nor

mal

ized

Cel

l Ind

ex

1.2

1.0

0.8

0.6

0.4

0.2

0.00.0

Time (in Hour)5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0


Documents

PM-CAR1035 CD19-CD22-4-1BB-CD3 ZETA PMC-250€¦ · in Figure 1). ProMab has also generated CAR-T cells and CAR-NK (Natural Killer) effector cells against cancer target cells that